Senior insider sale
ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$1.62M
35.41K shares
What this filing means
ORBIMED ADVISORS LLC plans to sell 35.41K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $1.62M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/23/2026ACC: 0000947871-26-000650
Director10% Owner
Since Mar 2020
35.41K
Shares to sell
$1.62M
Approx. market value
26.32K
Acquired (3 months)
2
Planned
1 completed
Securities Acquired — Last 3 Months1
Merger
N/A
2/23/2023
26.32KTotal acquired26.32K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
2/23/2023 | Merger N/A | 26.32K | — |
| Total | 26.32K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
9.09K
Market value
$409.1K
6/15/2026
Planned — Approximate Date
Nasdaq Stock MarketPlanned
Units to sell
1.48K
Market value
$67.9K
6/22/2026
Nasdaq Stock MarketPlanned
Units to sell
24.85K
Market value
$1.14M
6/22/2026
Total
Units
35.41K
Value
$1.62M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
6/15/2026 | 9.09K | $409.1K | — | Completed |
| Planned — Approximate Date | ||||
6/22/2026 | 1.48K | $67.9K | Nasdaq Stock Market | Planned |
6/22/2026 | 24.85K | $1.14M | Nasdaq Stock Market | Planned |
| Total | 35.41K | $1.62M | ||